
usd oct pm et
summari engag discoveri develop commerci treatment
infect respiratori disord cardiovascular condit cancer
price-to-earnings oper ep
risk assess reflect gilead abil increas
domin hiv market share off-set slow hepat
 market see opportun oncolog emerg
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
follow revenu declin
anticip sale
grow billion well-known
decay sale hcv franchis
deceler expect hcv sale
declin approxim billion
billion patient
cure competit market like
hand expect hiv
franchis continu grow
expect gener competit begin
erod hiv leadership sale
hiv antivir rose
billion driven tenofovir alafenamid taf
base drug biktarvi expect hiv
sale grow similar amount
took million charg
relat discontinu research
develop kite anti-bcma
program acquir kite pharma
despit setback top
prioriti capit alloc continu
portfolio tuck-in either
partnership follow dividend
find share trade
ep near fair valu
hcv franchis declin
expect sale hiv drug expand see
potenti franchis
current includ one commerci
therapi yescarta expect surpass
annual sale rather use
signific financi flexibl make
larg acquisit enter
collabor agreement galapago
glpg juli up-front payment
equiti invest return
gain access glpg drug discoveri
platform drug portfolio contain six
molecul clinic trial
preclin program glpg
promis candid glpg
idiopath pulmonari fibrosi glpg
osteoarthr
risk recommend target price
includ weaker-than-expect sale key
product pipelin failur
target price
ep estim
compar three-year forward price-to-earnings
rang
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview research-bas biopharmaceut compani
discov develop commerci innov medicin area unmet medic need gild
primari area focu includ hiv/aid liver diseas hematology/oncolog
inflammation/respiratori diseas oper countri world-wide end
gild research develop pipelin includ activ clinic studi
phase clinic trial addit complet collabor partnership strateg
invest earli market product across primari area
focu
total product sale billion sale come gild
largest franchis product sale hiv franchis gener billion sale gild hiv
franchis matur face increas competit work defend
franchis launch newer effect therapi success launch biktarvi
once-daili singl tablet tripl regimen approv fda februari
european commiss june
gild hiv franchis follow compani chronic hepat viru hcv franchis achiev
billion sale billion sale gild hcv franchis
declin patient becom cure
outsid gild key therapeut franchis hiv hcv see near-term potenti commerci
product yescarta non-hodgkin lymphoma clinic candid selonsertib treatment
nash filgotinib treatment rheumatoid arthriti
competit environ oper highli competit environ compani face
signific competit global pharmaceut biotechnolog compani special
pharmaceut firm gener drug manufactur gild product compet commerci
avail product base primarili efficaci safeti toler accept doctor eas patient
complianc eas use price insur reimburs coverag distribut market
gild product matur privat insur govern payer often reduc amount
reimburs patient increas pressur reduc price new brand gener
product introduc major market gild abil maintain price market share may
major develop juli enter collabor agreement galapago
glpg up-front payment equiti invest return gain access glpg
drug discoveri platform drug portfolio contain six molecul clinic trial
juli presid ceo john milligan announc would step end year new
ceo daniel oday took march prior oday serv ceo roch
pharmaceut appoint day senior manag line-up experienc
signific amount chang
octob acquir kite pharma billion expand presenc cell therapi
field month kite gene-therapi yescarta becam first fda-approv chimer antigen
receptor cell therapi yescarta treat adult non-hodgkin lymphoma
chemotherapi fail second fda-approv gene therapi took
million charg relat discontinu kite anti-bcma program treatment
multipl myeloma acquir kite pharma
financi trend gild revenu declin year-over-year billion primarili due
declin hcv franchis expect declin hcv franchis deceler next
year adjust ep free cash flow
billion billion march net cash posit
execut vice-president corpor
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
measur taken legisl regulatori
bodi lower drug price
democrat appear motiv
address drug price still think
suffici bipartisan impetu effect
signific chang near futur
anoth sourc price pressur drug
manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price especi sinc
major pbm merg major insur
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
fda-approv biosimilar
manufactur aggress use patent
law commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
year-to-d septemb
compar rise valu
 composit index
declin
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newli approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
recent year mega-d
announc bristol-my
squibb acquisit celgen
celg acquisit
botox manufactur allergan matur
biopharmaceut firm look off-set
lost revenu expir patent fail
ventur promis late-stag pipelin
addit exampl think gilead
scienc could
interest larg collabor
agreement biotechnolog compani
low debt level attract valuat
rel industri make
think investor interest biotechnolog
stock mute recent high drug
price come heighten scrutini
 polit apparatu last
year despit talk lower drug
price seen particularli sever
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain hold opinion share gilead scienc
inc lower target below-p
ep estim expect sale continu
declin near futur ep vs higher
estim rais ep ep
sale declin billion sale hepat treatment
continu declin million billion meanwhil hiv
product sale grew billion billion primarili due continu
uptak product contain emtricitabin ftc tenofovir alafenamid taf
particularli recently-launch biktarvi readout quarter
filgotinib finch phase studi posit encourag
abil file new drug applic nda conting upon data
manta phase studi slower-than-expect enrol rate
search new ceo continu /kevin huang cfa
keep target below-p
forward ep estim see continu declin sale
ep vs ahead view much lower
tax rate rais ep estim util
tax rate sale fell narrow
forecast declin hiv product sale solid rise
robust uptak new product descovi genvoya biktarvi odefsey
yet sale hepat hcv franchis fell
increas competit lower new patient start announc presid
ceo john milligan step year end mr milligan ceo
less three year face challeng rapidli declin hcv
product sale yet encourag effort expand oncolog
gene therapi primarili last year acquisit kite
analyst research note compani news
et cfra reiter hold opinion share inc
lower target price base
multipl vs three-year rang
ep estim ep vs
consensu rais ep revenu
billion million consensu expect overal
quarter result unev mostli line expect hiv
product sale expand billion yoy billion driven
world-wide biktarvi sale grew sequenti yoy
billion key focu continu pipelin capit
alloc appear lack combin clinic candid
could meaning acceler top- bottom-lin growth next
sever year manag team gone signific chang
recent might compani yet made move
materi bolster late-stag pipelin /kevin huang cfa
et cfra maintain hold opinion share inc
lower target base multipl
vs rang ep
estim ep vs exceed estim
primarili driven faster-than-expect adopt biktarvi hiv
world-wide biktarvi sale surg yoy million million
lift ep revenu grew billion
total product sale stay roughli flat yoy billion
earlier month announc collabor agreement
galapago glpg make billion up-front payment
equiti invest billion return gain access glpg
drug discoveri platform drug portfolio contain six molecul
clinic trial preclin program glpg
promis candid glpg idiopath pulmonari fibrosi glpg
osteoarthr /kevin huang cfa
et cfra maintain hold opinion share inc
maintain target base multipl
vs rang ep estim
lift ep ep
ep vs consensu
lower-than-expect oper expens revenu grew billion
total product sale grew billion product sale
europ declin year-over-year million due lower patient
start gener competit hiv product sale grew billion
billion primarili higher sale volum
continu uptak biktarvi new ceo daniel day comment
top prioriti capit alloc portfolio tuck-in either
 partnership follow dividend share buyback given
comment expect make larg acquisit time soon
et cfra maintain hold opinion share inc
lower target below-p
ep estim continu expect sale
declin primarili hcv drug sale ep vs
lower estim larg
higher-than-expect oper expens support busi growth lower
ep initi ep
revenu declin billion hcv sale declin million
billion meanwhil hiv product sale grew
billion billion prior-year period primarili due continu
uptak product contain emtricitabin ftc tenofovir alafenamid
taf particularli recently-launch biktarvi manag
sound eager alloc capit toward opportun
compani may wait incom ceo daniel day start march
up-to-spe compani /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share declin usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
